AI assistant
ImmunityBio, Inc. — Director's Dealing 2018
Aug 30, 2018
31529_dirs_2018-08-29_79410ff7-1c82-4b4e-bcbf-5af4ac49a836.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NantKwest, Inc. (NK)
CIK: 0001326110
Period of Report: 2018-08-27
Reporting Person: Nelson Sonja (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-08-27 | Stock Option (right to buy) | $3.07 | A | 200000 | Acquired | 2028-08-27 | Common Stock (200000) | Direct |
Footnotes
F1: Subject to the award recipient's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the option shall vest as follows: twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on August 27, 2019, and thereafter the remaining shares subject to the option shall vest and become exercisable in equal monthly installments over thirty six (36) months, such that the option will be fully vested and exercisable on August 27, 2022.